New Candidate Vaccines To Prevent Tuberculosis: Preclinical Assessment Of Efficacy, Safety And Mechanism Of Protection
Funder
National Health and Medical Research Council
Funding Amount
$594,133.00
Summary
Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.
Antibiotics have different effects on our own bacterial ecology, with sometimes unexpected detrimental effects. In this project, we will study this in detail and particularly address the question of 'good' and 'bad' antibiotics and how to identify them. National antibiotic policy and the deployment of 'decontamination' strategies in the critically ill are directly related issues and we expect to inform these important policy debates.
Plasmid Specialisation Modules, Microbial Husbandry And Microbiome Resilience
Funder
National Health and Medical Research Council
Funding Amount
$645,005.00
Summary
The epidemiology of plasmids is chiefly determined by small genetic modules that control their entry to cells, their stability after entry, and their capacity to exclude other related plasmids. Understanding this is important for understanding transmission of antibiotic resistance. It is also essential for our newly proven approach to remove resistance plasmids from bacteria.
Harnessing The Type VI Secretion System ‘combat’ Arsenal Of A. Baumannii As A Source Of New Antimicrobials And Antimicrobial Targets
Funder
National Health and Medical Research Council
Funding Amount
$521,557.00
Summary
Infections caused by drug-resistant bacteria represent one of the greatest threats to human health. There is an urgent need to develop novel drugs and treatment strategies to combat infections by these drug-resistant organisms. We have shown that the bacteria A. baumannii uses a needle-like system to deliver lethal toxins into competitors. We will characterize these toxins so that we can manipulate them as weapons for controlling infections with multi-drug resistant bacteria.
Severe sepsis is characterised by organ dysfunction secondary to infection, typically bacterial. We will quantify bacteria in the bloodstream of patients with septic shock, the most severe form of sepsis, to determine the relationship between bacterial load and clinical outcomes. We hypothesise that the bacterial load on presentation and the change in bacterial load over time determines survival and the evolution of organ failure in patients with septic shock.
Conquering Schistosomiasis In China: The Last Mile
Funder
National Health and Medical Research Council
Funding Amount
$2,432,780.00
Summary
Schistosomiasis (Bilharzia), caused by Schistosoma bloodflukes, is an ancient disease in the People’s Republic of China (PRC). After decades of control, the Chinese authorities have slated their intention to eliminate the disease by 2020. However, current diagnostic methods underestimate the true infection rates so we contend this target is unattainable. Supplementation of current control measures with additional public health interventions will be required to achieve the goal of elimination.
Novel Insights Into The Mechanisms Of How Chikungunya Virus Cause Disease In Humans
Funder
National Health and Medical Research Council
Funding Amount
$554,808.00
Summary
Many of the most dangerous and easily transmitted infectious agents are viruses. The emergence of chikungunya virus globally and the recognition of this pathogen in the aetiology of chronic diseases show the need for a better understanding of how the virus cause disease. The expected outcomes are a better understanding of human alphaviral diseases, with a view to improving prevention and treatment strategies to reduce the disease burden of CHIKV and related viruses.
Using High-throughput Genomics To Reveal The Deleterious Genetic Changes That Underlie Paediatric Leukoencephalopathies
Funder
National Health and Medical Research Council
Funding Amount
$1,003,712.00
Summary
There has been an explosion of high-throughput DNA sequencing technologies in the past five years, which have the potential to completely revolutionise medicine and scientific research. Here we present a series of studies showing the successful application of this technology to children with genetic disorders of the central nervous system. This proposal seeks to expand this study to a large cohort of similarly affected paediatric patients.
Improving Patient Safety In Radiation Therapy With The Watchdog Real-time Treatment Delivery Verification System
Funder
National Health and Medical Research Council
Funding Amount
$593,742.00
Summary
Radiation therapy is a highly effective cancer treatment with extremely high doses delivered using very complex treatment machines. Unfortunately errors have occurred resulting in cases of patient death and mistreatment. We have developed a novel method to assess the treatment delivery in real-time to prevent errors. The method uses imaging devices that are already present on the treatment machine meaning that this method could have a major impact on patient safety in modern radiation therapy.
Design And Application Of New Nanomaterials Theranostic Platforms For Targeted Treatment Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$530,626.00
Summary
The project aims to develop intelligent drugs that attract to malignant tumors like magnets. These powerful, next-generation chemotherapy drugs seek out cancerous cells, allowing physicians to see exactly where tumours lie. Nanoparticles inside the drugs then switch on upon contact with X-ray radiation beams. This new method, which can diagnose, deliver targeted therapy and monitor the response to therapy all at the same time, would reduce the amount of radiation needed to kill cancer cells.